Alzheimer's Disease Drug Development: Research and Development Ecosystem

ISBN-13: 9781108838665 / Angielski / Twarda / 2022 / 574 str.

Las Vegas) Jeffrey Cummings (University of Nevada; Las Vegas) Jefferson Kinney (University of Nevada;Howard Fillit

Opis

Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Recenzje

'The book occupies a unique niche among similar titles in the area, presenting the state-of-the-art in Alzheimer's disease drug development from a drug discovery perspective, a clinical perspective, and a financial perspective.' Marc A. Ilies, Doody's Review

Spis treści

Part I. Advancing Alzheimer therapies in a collaborative science ecosystem; Part II. Non-Clinical assessment of Alzheimer candidate drugs; Part III. Alzheimer clinical trials; Part IV. Imaging and biomarker development in Alzheimer drug discovery; Part V. Academic drug development programs; Part VI. Public-Private partnerships in Alzheimer drug development; Part VII. Funding and financing Alzheimer drug development.